November 4, 2011 -- ImmunoBiology Ltd (ImmBio), a Cambridge, UK vaccine company, has joined with Sinopharm Vaccine Institute, a part of CNBG (China National Biotech Group), to co-develop T-BioVax, ImmBio’s proprietary TB vaccine. The goal of the partnership is to bring the T-BioVax vaccine through SFDA approval and market it in China initially. More details....